COVID-19 - November 22, 2021
EMA issues advice on use of molnupiravir for COVID-19 treatment
EMA’s human medicines committee (CHMP) has issued advice on the use of Merck’s (known as MSD outside the United States and Canada) Lagevrio (also known as molnupiravir or MK 4482) for the treatment of COVID-19. The medicine, which is currently not authorized in the EU, can be used to treat adults with COVID-19 who do […]
COVID-19 - November 5, 2021
Merck’s COVID-19 pill approved in the UK
Merck and Ridgeback’s Molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world. U.K.’s Medicines and Healthcare Products Regulatory Agency authorizes Molnupiravir for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. In the U.K., LAGEVRIO (lah-GEV-ree-oh) is […]
Clinical Trials - August 11, 2021
BioInvent enters clinical trial collaboration
BioInvent International has entered into a second clinical trial collaboration and supply agreement with MSD. The two companies will evaluate the combination of one of BioInvent’s anti-TNFR2 antibodies, BI-1808, and MSD’s anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer. “We are very pleased we have reached […]
Working as a - December 14, 2020
A passion for the scientific side of medicine
For some people, testing the same thing over and over – tweaking, refining and then trying again – would seem tedious. For Charlotte Aagaard, however, trial-and-error to obtain final results are what fuels her passion for her career. “When at a certain time I was open for different opportunities, I worked with human papillomavirus (HPV) […]
Agreement - January 16, 2020
Microsoft and MSD in strategic partnership for Nordic and Baltic life science
The two companies have agreed on a partnership for the Nordic and Baltic markets with the aim to support healthcare. One possible field of cooperation is the use of cutting-edge technique, such as artificial intelligence, to support early diagnosis for i.a. lung cancer, they state. “The Nordic and Baltic states are at the forefront of […]
Clinical Trials - August 8, 2019
AstraZeneca’s PAOLA-1 trial met primary endpoint
AstraZeneca and MSD have announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza(olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gene mutations. The second positive Phase III trial with Lynparza The trial met […]